Can a heart drug solve kidney transplant Patients' phosphate problem?
NCT ID NCT06824454
First seen Jun 12, 2026 · Last updated Jun 13, 2026 · Updated 1 time
Summary
This study tests whether dipyridamole, a drug used for heart conditions, can raise phosphate levels in kidney transplant patients who develop low phosphate (hypophosphatemia). About 90 adult kidney transplant recipients will receive dipyridamole or a placebo. The goal is to see if the drug improves phosphate levels and reduces the need for phosphate supplements.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPOPHOSPHATEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
RECRUITINGStanford, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.